{"id":"eptotermin-alfa","rwe":[{"pmid":"27324640","year":"2016","title":"Bone morphogenetic protein 7 and autologous bone graft in revision surgery for non-union after lumbar interbody fusion.","finding":"","journal":"Archives of orthopaedic and trauma surgery","studyType":"Clinical Study"},{"pmid":"26747920","year":"2015","title":"Clinical effectiveness of Osigraft in long-bones non-unions.","finding":"","journal":"Injury","studyType":"Clinical Study"},{"pmid":"24074829","year":"2013","title":"Cost effectiveness of tibial nonunion treatment: A comparison between rhBMP-7 and autologous bone graft in two Italian centres.","finding":"","journal":"Injury","studyType":"Clinical Study"}],"tags":[{"label":"Biologic","category":"modality"},{"label":"M05BC02","category":"atc"},{"label":"Active","category":"status"},{"label":"Nonunion of fracture","category":"indication"},{"label":"Olympus Biotech International Limited","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Olympus Biotech International Limited","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=EPTOTERMIN ALFA","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:15:48.527133+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:15:53.960601+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:15:48.599537+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EPTOTERMIN ALFA","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:15:54.308132+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Activin receptor type-1 agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:15:55.714387+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108594/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:15:55.309727+00:00"}},"allNames":"osigraft","offLabel":[],"synonyms":["eptotermin alfa","osigraft","human recombinant bone morphogenetic protein 7","rhBMP-7"],"timeline":[{"date":"2001-05-17","type":"positive","source":"DrugCentral","milestone":"EMA approval (Olympus Biotech International Limited)"}],"approvals":[{"date":"2001-05-17","orphan":false,"company":"Olympus Biotech International Limited","regulator":"EMA"}],"brandName":"Osigraft","ecosystem":[{"indication":"Nonunion of fracture","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"modality":"Biologic","explanation":"","oneSentence":"","technicalDetail":"Osigraft (EPTOTERMIN ALFA) is a small molecule that likely acts through a specific receptor or pathway to stimulate the expression of genes involved in bone formation and healing, although the exact mechanism is not well-documented."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5175","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=EPTOTERMIN%20ALFA","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EPTOTERMIN ALFA","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T11:00:35.318124","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:15:57.017193+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"eptotermin alfa","indications":{"approved":[{"name":"Nonunion of fracture","source":"DrugCentral","snomedId":302941001,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00456157","phase":"PHASE1","title":"A Phase 1, Double-Blind, Randomized, Single Dose Escalation Safety Study of Intra-articular OP-1 in Subjects With Osteoarthritis of the Knee","status":"COMPLETED","sponsor":"Stryker Biotech","startDate":"2007-03","conditions":["Osteoarthritis of the Knee"],"enrollment":33,"completionDate":"2008-11"}],"_emaApprovals":[{"date":"2001-05-17","status":"Authorised","company":"Olympus Biotech International Limited"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"012781","UNII":"IT063R5MY0","INN_ID":"7989","UMLSCUI":"C1445625","chemblId":"CHEMBL2108594","ChEMBL_ID":"CHEMBL2108594","KEGG_DRUG":"D07437","DRUGBANK_ID":"DB11631","SNOMEDCT_US":"412029000"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Olympus Biotech International Limited","relationship":"Original Developer"}],"publicationCount":3,"therapeuticAreas":["Bone"],"atcClassification":{"source":"DrugCentral","atcCode":"M05BC02","allCodes":["M05BC02"]},"biosimilarFilings":[],"originalDeveloper":"Olympus Biotech International Limited","recentPublications":[{"date":"2016 Aug","pmid":"27324640","title":"Bone morphogenetic protein 7 and autologous bone graft in revision surgery for non-union after lumbar interbody fusion.","journal":"Archives of orthopaedic and trauma surgery"},{"date":"2015 Dec","pmid":"26747920","title":"Clinical effectiveness of Osigraft in long-bones non-unions.","journal":"Injury"},{"date":"2013 Dec","pmid":"24074829","title":"Cost effectiveness of tibial nonunion treatment: A comparison between rhBMP-7 and autologous bone graft in two Italian centres.","journal":"Injury"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Olympus Biotech International Limited","companyId":"olympus-biotech-international-limited","modality":"Recombinant protein","firstApprovalDate":"2001","aiSummary":"Osigraft, also known as OP-1, is a protein that acts as an agonist for the bone morphogenetic protein receptor type-1A. It is being studied as a potential treatment for osteoarthritis of the knee through intra-articular injection.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2001-05-17T00:00:00.000Z","mah":"Olympus Biotech International Limited","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":"2001-05-17T00:00:00.000Z","mah":"Olympus Biotech International Limited","brand_name_local":"Osigraft","application_number":"EMEA/H/C/000293"},{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":"2009-02-19T00:00:00.000Z","mah":"Olympus Biotech International Limited","brand_name_local":"Opgenra","application_number":"EMEA/H/C/000819"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:15:57.017193+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}